SY So-Young International ADS (N Shares)

HOOKIPA Pharma To Report Third Quarter 2020 Financial Results on November 12, 2020

HOOKIPA Pharma To Report Third Quarter 2020 Financial Results on November 12, 2020

NEW YORK and VIENNA, Austria, Nov. 03, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release financial results for the third quarter ended September 30, 2020 before the market opens on Thursday, November 12, 2020.

The Company will not be conducting a conference call in conjunction with this earnings release. Until otherwise noted, the Company will only conduct an earnings conference call in conjunction with its fourth quarter earnings releases.

About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.

HOOKIPA’s proprietary arenavirus-based technologies, non-replicating (VaxWave®) and replicating (TheraT®), induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.

HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.

In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.

Find out more about HOOKIPA online at .

MediaInvestors
Nina WaibelMatt Beck
Senior Director - CommunicationsExecutive Director - Investor Relations
  
Media enquiries 
Instinctif Partners 
 
+44 (0)20 7457 2020 
EN
03/11/2020

Underlying

SYSo-Young International ADS (N Shares)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on So-Young International ADS (N Shares)

 PRESS RELEASE
Free
SY So-Young Intern...

So-Young Announces Receipt of Withdrawal of Buyer Group’s Going Privat...

So-Young Announces Receipt of Withdrawal of Buyer Group’s Going Private Proposal BEIJING, Oct. 21, 2022 (GLOBE NEWSWIRE) -- So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that the special committee of the Company’s board of directors (the “Board”) has received a letter from Mr. Xing Jin, Chairman of the Board and Chief Executive Officer of So-Young (“Mr. Jin”), stating that Mr. Jin would withdraw the non-bind...

October 21, 2022 1 EN
 PRESS RELEASE
Free
SY So-Young Intern...

So-Young Reports Unaudited Second Quarter 2022 Financial Results

So-Young Reports Unaudited Second Quarter 2022 Financial Results BEIJING, Aug. 16, 2022 (GLOBE NEWSWIRE) -- So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Financial Highlights Total revenues were RMB309.1 million (US$46.1 million1), a decrease of 31.6% from RMB451.8 million in the same period of 2021.Net loss att...

August 16, 2022 1 EN
 PRESS RELEASE
Free
SY So-Young Intern...

So-Young to Report Second Quarter 2022 Financial Results on August 16,...

So-Young to Report Second Quarter 2022 Financial Results on August 16, 2022 BEIJING, Aug. 09, 2022 (GLOBE NEWSWIRE) -- So-Young International Inc. (NASDAQ: SY) (“So-Young” or the “Company”), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that it will report its financial results for the second quarter ended June 30, 2022, before U.S. markets open on August 16, 2022. So-Young's management will hold an earnings conference call on Tuesday, August 16, 2022, at 7:30 AM U.S. Eastern T...

August 9, 2022 1 EN
 PRESS RELEASE
Free
SY So-Young Intern...

So-Young Announces Receipt of Minimum Bid Price Notice from Nasdaq

So-Young Announces Receipt of Minimum Bid Price Notice from Nasdaq BEIJING, July 18, 2022 (GLOBE NEWSWIRE) -- So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that it has received a written notification from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) dated July 15, 2022, indicating that for the last 30 consecutive business days, the closing bid price of the Comp...

July 18, 2022 1 EN
 PRESS RELEASE
Free
SY So-Young Intern...

So-Young Reports Unaudited First Quarter 2022 Financial Results

So-Young Reports Unaudited First Quarter 2022 Financial Results BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the first quarter ended March 31, 2022. First Quarter 2022 Financial Highlights Total revenues were RMB300.3 million (US$47.4 million1), a decrease of 16.5% from RMB359.6 million in the same period of 2021, exceeding the ...

May 23, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch